Principal component analysis of flow-volume curves in COPDGene to link spirometry with phenotypes of COPD.
COPD
Computed tomography
Maximal expiratory flow-volume curve
Principal component analysis
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
19 Jan 2023
19 Jan 2023
Historique:
received:
16
06
2022
accepted:
06
01
2023
entrez:
19
1
2023
pubmed:
20
1
2023
medline:
24
1
2023
Statut:
epublish
Résumé
Parameters from maximal expiratory flow-volume curves (MEFVC) have been linked to CT-based parameters of COPD. However, the association between MEFVC shape and phenotypes like emphysema, small airways disease (SAD) and bronchial wall thickening (BWT) has not been investigated. We analyzed if the shape of MEFVC can be linked to CT-determined emphysema, SAD and BWT in a large cohort of COPDGene participants. In the COPDGene cohort, we used principal component analysis (PCA) to extract patterns from MEFVC shape and performed multiple linear regression to assess the association of these patterns with CT parameters over the COPD spectrum, in mild and moderate-severe COPD. Over the entire spectrum, in mild and moderate-severe COPD, principal components of MEFVC were important predictors for the continuous CT parameters. Their contribution to the prediction of emphysema diminished when classical pulmonary function test parameters were added. For SAD, the components remained very strong predictors. The adjusted R The shape of the maximal expiratory flow-volume curve as analyzed with PCA is not an appropriate screening tool for early disease phenotypes identified by CT scan. However, it contributes to assessing emphysema and SAD in moderate-severe COPD.
Sections du résumé
BACKGROUND
BACKGROUND
Parameters from maximal expiratory flow-volume curves (MEFVC) have been linked to CT-based parameters of COPD. However, the association between MEFVC shape and phenotypes like emphysema, small airways disease (SAD) and bronchial wall thickening (BWT) has not been investigated.
RESEARCH QUESTION
OBJECTIVE
We analyzed if the shape of MEFVC can be linked to CT-determined emphysema, SAD and BWT in a large cohort of COPDGene participants.
STUDY DESIGN AND METHODS
METHODS
In the COPDGene cohort, we used principal component analysis (PCA) to extract patterns from MEFVC shape and performed multiple linear regression to assess the association of these patterns with CT parameters over the COPD spectrum, in mild and moderate-severe COPD.
RESULTS
RESULTS
Over the entire spectrum, in mild and moderate-severe COPD, principal components of MEFVC were important predictors for the continuous CT parameters. Their contribution to the prediction of emphysema diminished when classical pulmonary function test parameters were added. For SAD, the components remained very strong predictors. The adjusted R
INTERPRETATION
CONCLUSIONS
The shape of the maximal expiratory flow-volume curve as analyzed with PCA is not an appropriate screening tool for early disease phenotypes identified by CT scan. However, it contributes to assessing emphysema and SAD in moderate-severe COPD.
Identifiants
pubmed: 36658542
doi: 10.1186/s12931-023-02318-4
pii: 10.1186/s12931-023-02318-4
pmc: PMC9854102
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20Subventions
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 11N3922N
Organisme : NIH HHS
ID : R01-089897
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Int J Chron Obstruct Pulmon Dis. 2019 Feb 14;14:409-418
pubmed: 30863041
N Engl J Med. 1978 Jun 8;298(23):1277-81
pubmed: 651978
Respir Res. 2013 Nov 19;14:131
pubmed: 24251975
Sci Rep. 2018 Nov 30;8(1):17484
pubmed: 30504791
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Respir Med. 2017 Feb;123:48-55
pubmed: 28137496
Ann Am Thorac Soc. 2018 Oct;15(10):1186-1196
pubmed: 30011374
Nervenarzt. 1998 Nov;69(11):968-74
pubmed: 9859118
JAMA Intern Med. 2015 Sep;175(9):1539-49
pubmed: 26098755
Respir Med. 2019 Sep;156:58-68
pubmed: 31437649
Ann Am Thorac Soc. 2019 Aug;16(8):982-989
pubmed: 30865842
Am J Med. 1972 Jun;52(6):725-37
pubmed: 5030170
Chronic Obstr Pulm Dis. 2019 Jul 24;6(3):256-266
pubmed: 31342731
Lancet Respir Med. 2018 Aug;6(8):591-602
pubmed: 30072106
Respir Physiol Neurobiol. 2016 Jun 15;227:69
pubmed: 26687468
N Engl J Med. 2019 Sep 26;381(13):1257-1266
pubmed: 31553837
J Clin Invest. 1951 Nov;30(11):1175-90
pubmed: 14888695
Nat Med. 2012 Nov;18(11):1711-5
pubmed: 23042237
Am J Respir Crit Care Med. 1999 Jan;159(1):179-87
pubmed: 9872837
N Engl J Med. 1970 Jun 4;282(23):1318-9
pubmed: 5442364
Sci Rep. 2019 Sep 11;9(1):13159
pubmed: 31511572
Lancet. 2016 Apr 30;387(10030):1817-26
pubmed: 27203508
Chest. 2013 May;143(5):1436-1443
pubmed: 23648907
COPD. 2010 Feb;7(1):32-43
pubmed: 20214461
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Chest. 1976 Jan;69(1):51-5
pubmed: 1244288
Respir Physiol Neurobiol. 2015 Dec;219:30-5
pubmed: 26275685